Trigeminal Autonomic Cephalgias (TACs) Emerging Therapy and TPP Insights

Thelansis’s “Trigeminal Autonomic Cephalgias (TACs) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Trigeminal Autonomic Cephalgias (TACs) Overview

Trigeminal autonomic cephalgias (TACs) are a distinct group of primary headache disorders characterised by strictly unilateral, severe trigeminal distribution pain invariably accompanied by ipsilateral cranial autonomic features — lacrimation, conjunctival injection, rhinorrhoea, ptosis, and eyelid oedema — reflecting activation of the trigeminovascular system and parasympathetic outflow via the sphenopalatine ganglion. The TAC spectrum encompasses cluster headache — the most prevalent and severe form — paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and cranial autonomic features (SUNA), and hemicrania continua, each distinguished by attack duration, frequency, and critically, differential therapeutic responsiveness. Cluster headache presents with excruciating periorbital or temporal attacks lasting 15-180 minutes, occurring in episodic or chronic patterns, with high-flow oxygen and subcutaneous sumatriptan as gold-standard acute therapies and verapamil as first-line prophylaxis; galcanezumab demonstrated efficacy in episodic cluster headache prevention. Paroxysmal hemicrania and hemicrania continua exhibit absolute, diagnostically pathognomonic responses to indomethacin. SUNCT and SUNA respond preferentially to lamotrigine. Secondary TAC mimics — pituitary adenoma, cavernous sinus pathology — mandate neuroimaging exclusion. Emerging neuromodulatory approaches including sphenopalatine ganglion stimulation offer options in refractory cluster headache. Prognosis varies with TAC subtype; accurate diagnosis, subtype-specific management, and multidisciplinary headache specialist involvement are indispensable to optimising patient outcomes and quality of life.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)